A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.
Launched by CENTOCOR, INC. · Sep 13, 2005
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
This is a clinical research study that will determine if there is a reduction in the signs and symptoms (such as back pain and stiffness) of patients with ankylosing spondylitis with infliximab therapy. This study will also study the safety of infliximab in patients with ankylosing spondylitis. The effect of infliximab on physical function, damage to joints and the quality of life in patients with ankylosing spondylitis will also be studied. Subjects received infusions of either placebo at weeks 0, 2, 6, 12, 18 and 5 mg/kg infliximab at weeks 24, 26, 30 and every 6 weeks through week 96, or...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have had a diagnosis of definite Akylosing Spondylitis for at least 3 months prior to screening
- • Have active disease with spinal pain
- • receiving or intolerant to standard anti-inflammatory agents
- Exclusion Criteria:
- • Have Rheumatoid Arthritis, systemic lupus erythematosus, or other inflammatory rheumatic disease
- • Have a documented history of fibromyalgia
- • Have total ankylosis
About Centocor, Inc.
Centocor, Inc. is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapies for autoimmune diseases, oncology, and other serious health conditions. With a strong focus on advanced research and clinical trials, Centocor leverages cutting-edge science and technology to create targeted biologic treatments that address unmet medical needs. Committed to improving patient outcomes, the company collaborates with healthcare professionals and regulatory bodies to ensure the safety and efficacy of its products, fostering a culture of excellence and integrity in all its clinical endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Centocor, Inc. Clinical Trial
Study Director
Centocor, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials